Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0605
D

Failure to Define Behaviors and Perform Gradual Dose Reduction for Psychotropic Medication

Rosemead, California Survey Completed on 05-23-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to properly identify and define specific problematic behaviors related to the use of quetiapine, an antipsychotic medication, for a resident diagnosed with dementia and psychosis. Documentation across the resident's physician orders, care plan, informed consent, and medication administration record was inconsistent, with different descriptions of the behaviors justifying the use of quetiapine. This inconsistency made it unclear why the medication was being used and whether its continued use was necessary for the resident. Additionally, the facility did not perform a required gradual dose reduction (GDR) for the resident's quetiapine therapy. Although the consultant pharmacist recommended a GDR, there was no evidence that the physician considered or responded to this recommendation, nor was there documentation of any clinical rationale for not attempting a GDR. The resident's dose of quetiapine remained unchanged since its initial prescription, and there was no record of psychiatric care or evaluation regarding the ongoing need for the medication. The facility's own policy requires that psychotropic medications be used only for specific, documented behaviors and that GDRs be attempted regularly unless clinically contraindicated. Despite this, the facility did not ensure that the use of quetiapine for this resident was clearly justified or that efforts were made to reduce the dosage as required. The Director of Nursing acknowledged these failures, noting the lack of clear documentation and follow-up regarding the use and monitoring of psychotropic medication for the resident.

An unhandled error has occurred. Reload 🗙